Halo Labs provides an update on Bophelo Bioscience and MedCan Partnership
The first of three planned 2021 crops is already underway with a quarter of the summer harvest in the ground.
TORONTO — Halo Labs Inc. provides an update to its Bophelo Bioscience & Wellness (Pty) Ltd. in Lesotho, South Africa and MedCan Ltd., the Company’s Malta offtake partner.
Bophelo continues to operate during the COVID-19 pandemic with special approval from the local police. The first of three planned 2021 crops is already underway with a quarter of the summer harvest in the ground; 1,983 clones have filled 500 square meters of canopy. Bophelo anticipates planting 6,000 autoflower plants to fill an additional 2,000 square meters of hoop houses by the end of January 2021. By April 2021, Bophelo expects the harvest to yield approximately 800 kilograms of trimmed flower and 800 kilograms of material to produce medicinal cannabis oils. Bophelo plans to plant second and third crop within 2021.
To support a planned year-round perpetual harvest and future exports to MedCan, Bophelo has also launched a Mother Program with diverse strains including those from OG DNA Genetics. Currently, 40 mother plants across ten strains are thriving. Bophelo plans to grow the mother stock to 150 plants across more strains by continuing the strain hunt.
In August 2020, Bophelo entered into an offtake agreement with MedCan for the sale of bulk cannabis biomass primarily into the European market. The Offtake Agreement specifies initial deliveries of up to 10,000 kilograms which are now expected to commence in 2021 and are anticipated to be completed in 2022. Bophelo has been working with Pharmaconsulta Limited, a Good Agricultural and Collection Practices focused consulting firm to obtain Maltese cGACP certification which Bophelo now anticipates achieving by mid 2021.